HDAC6 and Miyoshi myopathy: However HDAC6 inhibition impairs the upregulation of CD38 in MM cells by IFN-α and ATRA, which constitutes an aspect to take into account when considering the possibility of adding a HDACi to the combined treatment of daratumumab, IFN-α and ATRA [180].